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Brief report
The CALM1 core promoter polymorphism is not associated with hip
osteoarthritis in a United Kingdom Caucasian population
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Summary
Objective: A convincing genetic association with hip osteoarthritis (OA) of a functional single nucleotide polymorphism (SNP) in the core pro-
moter of the calmodulin 1 gene CALM1 was recently reported in a Japanese population. The T-allele of the SNP encoded OA susceptibility
and this was mediated by a reduced expression of CALM1. Our objective was to assess whether the SNP was also associated with hip OA in
UK Caucasians.
Methods: The SNP was genotyped in 920 cases that had undergone elective joint replacement of the hip due to end-stage primary OA and in
752 age-matched controls.
Results: Our study had greater than 97% power to observe an effect comparable to that seen in the Japanese study. However, there was no
signiﬁcant difference (P 0.05) in genotype or allele frequencies between our cases and our controls. There was also no signiﬁcant difference
when the cases were stratiﬁed by sex.
Conclusion: Our data on a cohort of 1672 individuals implies that the CALM1 core promoter polymorphism is not a risk factor for OA etiology in
Caucasians. Our study does not call in to question the veracity of the Japanese report. Instead it highlights the heterogenous nature of OA
genetic susceptibility.
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Cartilage
Repair
SocietyIntroduction
Through a genome-wide association study, a group recently
reported an association of a functional 16C to T transition
single nucleotide polymorphism (SNP) rs12885713 within
the core promoter region of the calmodulin 1 gene
CALM1 with hip osteoarthritis (OA) in a Japanese popula-
tion1. Calmodulin is an intracellular protein that binds to
Ca2þ and which interacts with a number of cellular pro-
teins2,3. The increased expression of CALM1 in OA joint
cartilage was demonstrated by the Japanese group, as
was the ability of calmodulin to up-regulate the expression
of COL2A1 and AGC1, the genes that encode the principal
cartilage proteins type II collagen and aggrecan, respectively.
Calmodulin therefore appears to be an important chon-
drogenic factor. Ca2þ-calmodulin signalling also inﬂuences
the chondrocyte response to mechanical load, an essential
facet of normal articular function.
Possessing two copies (i.e., a recessive model) of the
T-allele of SNP rs12885713 was a particular risk factor in
the Japanese, with an odds ratio (OR) of 2.56 and P value
of 0.00036. Functional studies demonstrated that the
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Received 10 June 2005; revision accepted 1 November 2005.29associated T-allele decreased CALM1 transcription. The in-
creased OA risk therefore appeared to be acting by reduc-
ing the amount of calmodulin synthesised which then
resulted in a decreased expression of COL2A1 and AGC1.
Our objective was to assess whether SNP rs12885713
was also associated with OA susceptibility in a Caucasian
population collected in the United Kingdom.
Patients and methods
CASEeCONTROL COHORT
The cases (n¼ 920; 547 females and 373 males) were
ascertained through the Nufﬁeld Orthopaedic Centre in Ox-
ford using the criteria of signs and symptoms of hip OA suf-
ﬁciently severe to require hip replacement surgery. All had
pain with rest and night symptoms of more than 6 months
duration. The radiological stage of the disease was
a Kellgren and Lawrence (KL) grade of 2 or more in all
cases with over 90% being grade 3 or 4. Inﬂammatory ar-
thritis (rheumatoid, polyarthritic or autoimmune disease)
was excluded, as was post-traumatic or post-septic arthritis.
No cases suggestive of a skeletal dysplasia or developmen-
tal dysplasia were included. The average age of the cases
at hip replacement surgery was 64 years with an age range
of 56e85 years. The controls comprised 752 individuals
(393 females and 359 males) with no signs or symptoms
of arthritis or joint disease (pain, swelling, tenderness or re-
striction of movement). The average age of the controls at5
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years. Due to ethical and ﬁnancial constraints the hip joints
of the controls were not subjected to radiographic analysis.
All cases and all controls were UK Caucasians.
GENOTYPING SNP rs12885713
The SNP was ampliﬁed using forward primer
5#GGCGGGACCAGGCGGGCAAG3# and reverse primer
5#CGTCCACGACACTCCCAGCACCACTGCCGGAGCGC
GAGTCGGC3#. The italic nucleotide in the reverse primer is
a G as opposed to the A that exists in the CALM1 sequence.
This forced change creates aBsaHI restriction enzyme site in
the C-allele of the SNP which is absent in the T-allele. The
polymerase chain reactions (PCRs) were supplemented
with 5% dimethyl sulfoxide (DMSO). The 146 bp PCR prod-
uct was then digested with BsaHI (New England Biolabs,
Hitchin, UK). A C-allele generates two fragments, of 101 bp
and 45 bp, whilst a T-allele remains uncut. Digestion prod-
ucts were electrophoresed through 3% agarose and scored
following ethidium bromide staining. A second PCR-restric-
tion enzyme genotyping assay was designed to conﬁrm the
accuracy of the original assay. The SNP was ampliﬁed using
forward primer 5#GCGGGAGGCCTGGCGAACCC3# and
reverse primer 5#GGGTACCTCCGATGCCGCTG3#. Nei-
ther of these two primers overlapped with the two primers
used in the BsaHI assay. The 273 bp product was then di-
gested with HpyCH4V. A C-allele remains uncut whereas
a T-allele generates two fragments, of 146 bp and 127 bp.
STATISTICAL ANALYSIS AND STATISTICAL POWER
Genotype and allele distributions in cases and controls
were compared using standard chi-square analysis-of-con-
tingency tables. ORs were calculated with 95% conﬁdence
intervals (95% CIs). For stratiﬁcation analysis, female cases
were compared to female controls, and male cases were
compared to male controls.
To conduct power calculations we used Quanto version
0.5 (http://hydra.usc.edu/gxe/)4,5 with the following options:
(1) 920 cases and 752 controls when using both males and
females, 547 female cases and 393 female controls, or 373
male cases and 359 male controls; (2) a recessive model as
used by the Japanese group1 or a dominant model; (3)
a population risk of OA of 5%; (4) a T-allele frequency of
57.9%, the frequency for our 752 controls; and (5) a signiﬁ-
cance level of 0.05.Results
POWER OF STUDY
Using the Quanto program we determined that our study
had greater than 97% power under both dominant and re-
cessive models to detect an OR of 2.40, the smallest OR
observed for SNP rs12885713 in the Japanese study1.
This power was applied for the entire study sample and
following stratiﬁcation by sex.
ASSOCIATION ANALYSIS
Table I lists the genotype and allele frequencies of SNP
rs12885713 in our cases and in our controls. The data
have also been stratiﬁed by sex. We compared the geno-
type frequencies between the cases and the controls, and
the allele frequencies between the cases and the controls.
None of the genotype or allele frequencies differed signiﬁ-
cantly (P 0.05). In the Japanese study1 possessing two
copies of the T-allele (genotype [TT], i.e., a recessive model)
was a particular risk factor. When we conducted this
analysis, there was no signiﬁcant difference between our
cases and our controls.
CONFIRMING THE ACCURACY OF THE GENOTYPING
OF SNP rs12885713
The allelic frequencies for SNP rs12885713 differed dra-
matically between our study and the Japanese study. For ex-
ample, in our controls (n¼ 752) the T-allele had a frequency
of 57.9% whereas in the Japanese controls (n¼ 375) the T-
allele had a frequency of 26.4%. This represented a highly
signiﬁcant difference (P< 0.0001). This large difference in
allele frequency for SNP rs12885713 is noted in the genome
databases. In Ensembl (http://www.ensembl.org/) the fre-
quency of the T-allele in 78 unrelated centre d’etude du
polymorphisme humain (CEPH) individuals of European an-
cestry is 83% whereas the frequency in 100 unrelated Japa-
nese is 32%. Such ethnic differences in allele frequency for
polymorphic markers are not unusual6. However, to be cer-
tain that our genotyping was accurate we designed a second
PCR-restriction enzyme genotyping assay that used sepa-
rate primers and a separate restriction enzyme (HpyCH4V)
to that used in our original genotyping assay. This second
assay was conducted on 90 control individuals. Exactly the
same genotypes were obtained for the two assays (data
not shown).Table I
Association of SNP rs12885713 between OA cases and controls from the UK
Group Genotype P value Genotype e recessive model P value Allele P value
TT TC CC TT TCþCC T C
All cases (n¼ 920) Count 296 478 146 0.84 296 624 0.90 1070 770 0.92
Frequency (%) 32.2 52.0 15.9 32.2 67.9 58.2 41.8
All controls (n¼ 752) Count 245 381 126 245 507 871 633
Frequency (%) 32.6 50.7 16.8 32.6 67.5 57.9 42.1
Female cases (n¼ 547) Count 187 274 86 0.75 187 360 0.97 648 446 0.67
Frequency (%) 34.2 50.1 15.7 34.2 65.8 59.2 40.8
Female controls (n¼ 393) Count 133 191 69 133 260 457 329
Frequency (%) 33.8 48.6 17.6 33.8 66.2 58.1 41.9
Male cases (n¼ 373) Count 109 204 60 0.84 109 264 0.62 422 324 0.71
Frequency (%) 29.2 54.7 16.1 29.2 70.8 56.6 43.4
Male controls (n¼ 359) Count 112 190 57 112 247 414 304
Frequency (%) 31.2 52.9 15.9 31.2 68.8 57.7 42.3
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CALM1 SNP RS12885713 AND THE ASPN D-REPEAT
POLYMORPHISM
The Japanese group that reported the CALM1 associa-
tion have also reported an association of large-joint OA to
an aspartic acid repeat polymorphism within the ASPN
gene on chromosome 9q22.317. ASPN codes for asporin,
which is an extracellular matrix (ECM) macromolecule
belonging to the small leucine-rich proteoglycan (SLRP)
family8,9. The aspartic acid repeat polymorphism was titled
the D-repeat and had 10 alleles encoding 10e19 D resi-
dues. Allele D14 was associated with hip OA and with
knee OA in Japanese. This association appeared to be
mediated by a particularly potent inhibitory effect of
allele D14 on the anabolic cytokine transforming growth
factor-b (TGF-b), which resulted in a reduced expression
of the type II collagen gene COL2A1 and of the aggrecan
gene AGC1. The associated alleles at CALM1 and ASPN
are therefore acting in the same manner, namely reducing
the expression of COL2A1 and AGC1. The Japanese inves-
tigators had therefore assessed whether CALM1 and ASPN
were working together in a combinatorial manner to
increase OA risk1. The genotype that was [TT] for the
CALM1 SNP rs12885713 and homozygous or heterozy-
gous with respect to the ASPN D14 allele proved to be
a particularly strong OA risk factor, but of low statistical cer-
tainty, with an OR of 13.16 (95% CI 1.66e104.06).
We have previously genotyped the ASPN D-repeat in the
same hip cohort and in the same controls that we have gen-
otyped here for the CALM1 SNP10. The D-repeat was not
associated in our hip cases. When we carried out the com-
binatorial analysis between the CALM1 SNP rs12885713
genotype [TT] and the ASPN allele D14 we did not detect
any evidence of a genotypic interaction (Table II). There
was also no evidence of an interaction between the
CALM1 [CT] genotype and ASPN allele D14.
Discussion
OA is a complex disease with both genetic and non-ge-
netic components11. Identifying OA risk alleles is an ardu-
ous task complicated by incomplete penetrance, variable
expression and a likely high degree of etiological heteroge-
neity between populations. A number of OA susceptibility
loci have been reported and some have been shown to
have a role in OA occurrence in more than one study11.
Our aim was to assess whether a functional SNP within
the core promoter of CALM1 that was strongly associated
with hip OA in Japanese had any relevance to hip OA in
a Caucasian population. We genotyped a large caseecon-
trol cohort of 1672 individuals. No association was detected.
Our power calculations revealed that we had greater than
97% power to detect an association comparable to that re-
ported in the Japanese. We conclude therefore that the
CALM1 promoter SNP does not inﬂuence OA susceptibility
in our cohort.
The absence of an association of the CALM1 functional
promoter SNP in our study does not call in to question the
Japanese report. Instead, it highlights the complex nature
of genetic susceptibility for common multifactorial diseases.
Environmental factors or other genetic factors that are more
prevalent in the Japanese may inﬂuence the extent to which
the CALM1 OA risk is manifest. One interesting difference
between Japanese and Caucasians is the shape of the pel-
vis. There are marked differences in pelvic morphometry
between the two populations, with acetabular dysplasiaT
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298 J. Loughlin et al.: CALM1 polymorphism and OA(AD) demonstrating a signiﬁcantly greater prevalence in the
Japanese12. Studies have suggested that AD modestly in-
creases the risk of hip OA13e15. In the Japanese CALM1
study 40% of the patients had AD1. However, when the Jap-
anese CALM1 data were stratiﬁed by the presence or ab-
sence of AD the association persisted in both groups,
implying that the association in Japanese is independent
of AD status. Another potentially signiﬁcant difference be-
tween the Japanese cohort and ours was the ascertainment
criteria used. Whereas we used the need for joint replace-
ment to ascertain our cases, the Japanese used symptoms
and radiological evidence of joint space narrowing and/or
the presence of osteophytes. It seems intuitively unlikely,
however, that a locus which is a risk factor for the develop-
ment of symptomatic and radiological OA cannot also be
a risk factor for OA that necessitates joint replacement. A
further difference between our study and the Japanese
was in the proportion of cases that were females. The
vast majority of the cases used in the Japanese study
were females (94%) whereas in our study the proportion
of female cases was 59%. Stratiﬁcation of our study by
sex did not reveal an association to our female cases.
An understanding of the reasons behind ethnic differences
in disease risk in response to DNA polymorphism requires
a complete knowledge of all potential risk factors and a com-
prehensive understanding of their interactions. When pre-
sented with a compelling association the most that
a geneticist can do at present is to test that association in
their cohort. Our analysis of the CALM1 promoter SNP im-
plies that it is not a risk factor for hip OA in the UK population.
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